137 related articles for article (PubMed ID: 25075060)
1. Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine.
De Iuliis F; Salerno G; Taglieri L; Vicinanza R; Lanza R; Scarpa S
Anticancer Res; 2014 Aug; 34(8):4287-91. PubMed ID: 25075060
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
[TBL] [Abstract][Full Text] [Related]
6. To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Nannini M; Nobili E; Di Cicilia R; Brandi G; Maleddu A; Pantaleo MA; Biasco G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):189-93. PubMed ID: 19151974
[TBL] [Abstract][Full Text] [Related]
7. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
Alagizy HA; Shehata MA; Hashem TA; Abdelaziz KK; Swiha MM
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):22-7. PubMed ID: 25528114
[TBL] [Abstract][Full Text] [Related]
8. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
10. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Kaufmann M; Maass N; Costa SD; Schneeweiss A; Loibl S; Sütterlin MW; Schrader I; Gerber B; Bauer W; Wiest W; Tomé O; Distelrath A; Hagen V; Kleine-Tebbe A; Ruckhaeberle E; Mehta K; von Minckwitz G;
Eur J Cancer; 2010 Dec; 46(18):3184-91. PubMed ID: 20797843
[TBL] [Abstract][Full Text] [Related]
11. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Gelmon K; Chan A; Harbeck N
Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.
Chen S; Yang Y; Jiao Y; Sun H; Yan Z
J BUON; 2021; 26(3):734-740. PubMed ID: 34268928
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Honma H
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2045-8. PubMed ID: 17197750
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
19. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine cardiac toxicity presenting as effort angina: a case report.
Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]